Control Bionics Ltd - Asset Resilience Ratio
Control Bionics Ltd (CBL) has an Asset Resilience Ratio of 0.95% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CBL liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Control Bionics Ltd's Asset Resilience Ratio has changed over time. See shareholders equity of Control Bionics Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Control Bionics Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Control Bionics Ltd market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$77.92K | 0.95% |
| Total Liquid Assets | AU$77.92K | 0.95% |
Asset Resilience Insights
- Limited Liquidity: Control Bionics Ltd maintains only 0.95% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Control Bionics Ltd Industry Peers by Asset Resilience Ratio
Compare Control Bionics Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Vitrolife AB
ST:VITR |
Medical Devices | 7.27% |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033 |
Medical Devices | 19.31% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 8.60% |
|
Lumos Diagnostics Holdings Ltd
AU:LDX |
Medical Devices | 9.40% |
|
T&R Biofab Co. Ltd
KQ:246710 |
Medical Devices | 0.12% |
|
Ok Biotech Co Ltd
TW:4155 |
Medical Devices | 0.32% |
|
Promimic AB
ST:PRO |
Medical Devices | 8.62% |
|
Memphasys Ltd
AU:MEM |
Medical Devices | 0.00% |
Annual Asset Resilience Ratio for Control Bionics Ltd (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Control Bionics Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.95% | AU$77.92K ≈ $55.14K |
AU$8.23 Million ≈ $5.83 Million |
+0.08pp |
| 2023-12-31 | 0.86% | AU$77.92K ≈ $55.14K |
AU$9.03 Million ≈ $6.39 Million |
+0.22pp |
| 2022-12-31 | 0.65% | AU$56.19K ≈ $39.76K |
AU$8.70 Million ≈ $6.15 Million |
+0.23pp |
| 2021-12-31 | 0.42% | AU$56.19K ≈ $39.76K |
AU$13.44 Million ≈ $9.51 Million |
+0.35pp |
| 2020-12-31 | 0.07% | AU$13.09K ≈ $9.26K |
AU$18.35 Million ≈ $12.99 Million |
-0.56pp |
| 2016-12-31 | 0.63% | AU$7.61 Million ≈ $5.39 Million |
AU$1.20 Billion ≈ $851.86 Million |
-- |
About Control Bionics Ltd
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia, North America, and internationally. It offers NeuroNode Trilogy, NeuroNode Duo, and Eye-gaze Duo systems that allow people with speech and movement difficulties to control a computer for speech generation, electroni… Read more